Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics Inc (RLMD)
:RLMD
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.46Last Year’s EPS
-0.59Same Quarter Last Year
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 70.00%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong progress in product development with promising Phase 2 data for NDV-01 and sepranolone, as well as a disciplined financial approach. However, there are concerns about increased cash usage and a decreased cash position.Company Guidance
During the Relmada Therapeutics First Quarter 2025 Earnings Call, the company provided guidance for its two primary product candidates, NDV-01 and sepranolone. NDV-01, a novel bladder cancer treatment, demonstrated promising Phase 2 data with an 85% overall response rate at three months and 100% disease-free status in seven evaluable patients at six months. The company highlighted NDV-01's potential to improve non-muscle invasive bladder cancer care due to its sustained-release formulation and impressive safety profile, with no treatment-related adverse events greater than Grade 1. Meanwhile, sepranolone, aimed at treating Prader-Willi syndrome and Tourette syndrome, showed a competitive 28% peak reduction in the primary clinical endpoint in Phase 2 trials. With a cash balance of $27 million and a clean balance sheet, Relmada is focused on advancing these programs through key clinical and regulatory milestones in 2025 and beyond.Addition of Promising Product Candidates
Relmada added two unique product candidates, NDV-01 for bladder cancer and sepranolone for Prader-Willi syndrome and Tourette syndrome, both with very encouraging Phase 2 data.
Positive Phase 2 Data for NDV-01
Initial proof-of-concept Phase 2 data for NDV-01 showed an overall response rate of 90% and a complete response in carcinoma in situ patients at 100%.
Strong Safety Profile for NDV-01
NDV-01 was well tolerated with no treatment-related adverse events greater than Grade 1.
Financial Position and Cost Management
Relmada has a $27.1 million cash balance and reported a decrease in net loss from $21.8 million in Q1 2024 to $17.6 million in Q1 2025.
Sepranolone's Potential in Treating Neurobehavioral Disorders
Sepranolone, with a broad safety database and promising Phase 2 results in Tourette syndrome, is expected to address sizeable underserved markets including Prader-Willi syndrome.
RLMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RLMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $0.40 | $0.39 | -2.50% |
Mar 27, 2025 | $0.30 | $0.30 | 0.00% |
Nov 07, 2024 | $3.26 | $3.28 | +0.61% |
Aug 07, 2024 | $3.24 | $2.30 | -29.01% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Relmada Therapeutics Inc (RLMD) report earnings?
Relmada Therapeutics Inc (RLMD) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Relmada Therapeutics Inc (RLMD) earnings time?
Relmada Therapeutics Inc (RLMD) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RLMD EPS forecast?
RLMD EPS forecast for the fiscal quarter 2025 (Q2) is -0.46.